Patrícia Silva, PhD, director of science content —

Pulmatrix, Inc., a biopharmaceutical company focused on inhaled therapies for serious pulmonary diseases, recently announced a new drug candidate called PUR1900 for the treatment of fungal infections associated with cystic fibrosis (CF). CF is a rare, life-threatening genetic disease in which a defective gene (CFTR) induces a salt imbalance, causing…

Protalix BioTherapeutics, Inc. recently announced that on June 12, 2015 Dr. Yosehp Shaaltiel, EVP of Research and Development, presented pre-clinical data on the company’s AIR DNaseTM (PRX-110) for cystic fibrosis (CF) treatment at the 38th European Cystic Fibrosis Conference, held in Brussels, Belgium. The oral presentation was entitled…

Vertex Pharmaceuticals Incorporated recently announced in a press release new data on its long-term PROGRESS study testing the investigational regimen ORKAMBI (lumacaftor/ivacaftor) for cystic fibrosis (CF). The data was presented at the 38th European Cystic Fibrosis Society (ECFS) Conference, June 10-13, 2015 held in Brussels, Belgium in…

New research is shedding light on a possible link between endometriosis in females who have cystic fibrosis. Cystic fibrosis (CF) is a genetic disorder caused by mutations to the cystic fibrosis transmembrane conductance regulator (CFTR) gene that mostly affects the lungs, but also the pancreas, liver, kidneys and intestine. The…

Celtaxsys has announced that the company’s phase 2 clinical trial to evaluate CTX-4430, its investigational treatment for cystic fibrosis (CF), will be supported by a $5 million grant from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The CFFT is the non-profit drug discovery and development affiliate of the Cystic Fibrosis…

Corbus Pharmaceuticals Holdings, Inc., a company focused on the development and commercialization of new therapies for rare, chronic, serious inflammatory and fibrotic diseases, recently announced that its President and Chief Scientific Officer Dr. Mark A. Tepper is presenting a poster (June 1-2) at the 2015 Cystic Fibrosis Foundation Research…

The Best Late Stage Product Development Company Award was recently granted to Parion Sciences by the Triangle Business Journal and accounting firm BDO. The company, which is focused on creating novel therapies for both pulmonary and ocular medical conditions, was presented with the award at an event in Cary, North Carolina, and is part of the third-annual…

Despite suffering from cystic fibrosis (CF), having spent most of her time during high school either at home or hospitalized and having undergone a double-lung transplant, Rachel Sweet will graduate high school on June 2nd, becoming yet another example of the determination seen in those who live with the disease.

In a recent agreement with the Indiana University Research and Technology Corp. (IURTC), La Jolla Pharmaceutical Co. acquired intellectual property rights covering next-generation derivatives of gentamicin, an antibiotic used in the treatment of several types of bacterial infections, namely heart, urinary tract, and pregnancy-related infections. Gentamicin treatment is effective…

Researchers at the University of Missouri–Columbia have discovered two key amino acids in the protein that is associated with cystic fibrosis (CF) — cystic fibrosis transmembrane conductance regulator (CFTR) protein. The study is entitled “Localizing a gate in CFTR” and was published in the journal…